Get the Stockscreener App
1.31
2.96%
-0.04
After Hours:
1.28
-0.03
-2.29%
Aspire Biopharma Holdings Inc stock is traded at $1.31, with a volume of 400.04K.
It is down -2.96% in the last 24 hours and down -65.53% over the past month.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
See More
Previous Close:
$1.35
Open:
$1.33
24h Volume:
400.04K
Relative Volume:
0.29
Market Cap:
$6.27M
Revenue:
-
Net Income/Loss:
$-27.39M
P/E Ratio:
-0.7796
EPS:
-1.6803
Net Cash Flow:
$-2.09M
1W Performance:
-0.76%
1M Performance:
-65.53%
6M Performance:
-90.90%
1Y Performance:
+0.00%
1-Day Range:
$1.20
$1.36
1-Week Range:
$1.20
$1.49
52-Week Range:
$1.20
$84.00
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
23150 FASHION DRIVE, SUITE 232, ESTERO
Compare ASBP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
1.31 | 6.47M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - Worcester Telegram
Aspire Biopharma Announces Private Placement to Strengthen Finances - TipRanks
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - BlueRidgeNow.com
Aspire Biopharma Holdings Signs Multiple Material Agreements - TradingView
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R)) - ACCESS Newswire
New Zofran-style powder aims to bring IV-speed nausea relief at home - Stock Titan
Major Financial Concerns Loom as Aspire Biopharma Troubles Deepen - StocksToTrade
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements - ACCESS Newswire
$21M cash boost aims to keep Aspire Biopharma on Nasdaq - Stock Titan
Aspire Biopharma Announces Reverse Stock Split - SouthCoastToday.com
Aspire Biopharma regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Nigeria
Aspire Biopharma Provides Q3 2025 Business Update - Corpus Christi Caller-Times
Aspire Biopharma regains Nasdaq minimum bid price compliance - MSN
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - itemonline.com
Aspire Biopharma Holdings files for Series A convertible preferred stock on Nasdaq By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings files for Series A convertible preferred stock on Nasdaq - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit - accessnewswire.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - DelmarvaNow.com
Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages - Yahoo Finance
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - The Times-Mail
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution - Finviz
Caffeine stick packs hit Palm Springs resorts ahead of Coachella - Stock Titan
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of AlprazolamGeneric Xanax(R)for Rapid Anxiety Relief - The Clarion-Ledger
ASBPWAspire Biopharma Holdings Inc Latest Stock News & Market Updates - stocktitan.net
Aspire Biopharma Holdings raises $2 million through debenture sale By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings raises $2 million through debenture sale - Investing.com
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):